A co-ultramicronized palmitoylethanolamide/luteolin composite mitigates clinical score and disease-relevant molecular markers in a mouse model of experimental autoimmune encephalomyelitis
Laboratory studyOther animalsWith luteolin (co-ultramicronised PEA/luteolin, PEALut)
This study tested palmitoylethanolamide together with luteolin (co-ultramicronised PEA/luteolin, PEALut). Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Laboratory study
- Subjects
- Mice with experimental autoimmune encephalomyelitis (EAE) induced by MOG35-55 immunisation
- Dose used in the study
- PEALut, 0.1 to 5 mg/kg, intraperitoneal, daily from day 11 after immunisation
- Duration
- Daily dosing from day 11, assessed to at least day 14 post-immunisation
- What was measured
- Daily clinical score of paralysis; expression of SAA1, TNF-alpha, IL-1beta, IFN-gamma, NLRP3, TLR2, Fpr2, CD137, T-cell receptor components and cannabinoid receptors CB1/CB2 in brainstem and cerebellum
What the authors reported
The study found:
- MOG-immunised mice developed ascending paralysis.
- PEALut dose-dependently improved clinical score.
- At 5 mg/kg it significantly reduced the raised SAA1, TNF-alpha, IL-1beta and IFN-gamma at day 14, and reduced the raised TLR2, Fpr2, CD137, T-cell receptor markers and CB2 expression.
- CB1 and MBP were unchanged in either group.
Limits of this study
A mouse model of induced autoimmune brain and spinal cord inflammation; it cannot show effect in people. The authors declare no competing interests.
Source
PubMed 31221190 · doi:10.1186/s12974-019-1514-4
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.